Business Description
Regulus Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US75915K1016
Description
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 139.94 | |||||
| Equity-to-Asset | 0.94 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.02 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 26.3 | |||||
| 3-Year EPS without NRI Growth Rate | 29.5 | |||||
| 3-Year FCF Growth Rate | 26.2 | |||||
| 3-Year Book Growth Rate | -35.3 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 86.38 | |||||
| 9-Day RSI | 72.54 | |||||
| 14-Day RSI | 63.34 | |||||
| 6-1 Month Momentum % | -42.8 | |||||
| 12-1 Month Momentum % | 17.21 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 19.06 | |||||
| Quick Ratio | 19.06 | |||||
| Cash Ratio | 17.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -44.2 | |||||
| Shareholder Yield % | -84.66 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -61.18 | |||||
| ROA % | -53.56 | |||||
| ROIC % | -370.19 | |||||
| 3-Year ROIIC % | 1737.09 | |||||
| ROC (Joel Greenblatt) % | -1377.15 | |||||
| ROCE % | -59.43 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.1 | |||||
| Price-to-Tangible-Book | 1.1 | |||||
| EV-to-EBIT | -0.4 | |||||
| EV-to-EBITDA | -0.4 | |||||
| EV-to-FCF | -0.41 | |||||
| Price-to-Net-Current-Asset-Value | 1.14 | |||||
| Price-to-Net-Cash | 1.22 | |||||
| Earnings Yield (Greenblatt) % | -250 | |||||
| FCF Yield % | -31.3 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers